You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Evolut™ TAVI is currently the only TAVI device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at one year.1LEARN ABOUT EVOLUT LOW RISK STUDY RESULTS FROM NEJM
Evolut TAVI 2.3 cm2 vs. SAVR 2.0 cm2
15% Larger EOAs
Evolut TAVI 8.6 mm Hg vs. SAVR 11.2 mm Hg
23% Lower Gradients
As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months1
5.3% TAVI vs. 6.7% SAVR
n = 1,468
EvolutTM TAVI showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalisations compared to SAVR2
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.
Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.